Cijena dionica i vijesti za Arbutus Biopharma Corp (ABUS) – Google Finance

Financije

Početna stranicaABUS • NASDAQ

Arbutus Biopharma Corp

4,26 $

16. ožu, 08:20:34 GMT -4 · USD · NASDAQ · Odricanje od odgovornosti

VrijednosnicaZemlja u kojoj se trguje vrijednosnicom: SADZemlja u kojoj se nalazi sjedište: SAD

Preth. zaklj. cijena

4,26 $

Godišnji raspon

2,71 $ - 5,10 $

Tržišna kapitalizacija

819,30 mil. USD

Prosječna količina

2,67 mil.

P/E omjer

-

Prinos dividende

-

Glavno tržište vrijednosnica

NASDAQ

Vijesti s tržišta

prije 38 minuta

New to The Street Broadcasts Episode Featuring FreeCast (NASDAQ:CAST), KLED.AI, PetVivo (OTCQB:PETV), EmpowerLit, and BlackBarn NYC on Bloomberg Television - March 21 at 6:30 PM EST

prije 42 minute

Cycurion (Nasdaq: CYCU) Announces Definitive Agreement to Acquire Federal Cybersecurity Firm and Reports Record Contracted Backlog Exceeding $150 Million

prije 46 minuta

Morgan Stanley's Mike Wilson: S&P 500 could trade toward 6,300 by early April

prije 51 minutu

Trump has 15 days to end the Iran war or markets face a brutal April repricing — from oil to the S&P 500

Severe oil shock could drag S&P 500 down to 5,400, Goldman warns

prije 57 minuta

How do companies get added to (& dropped from) the Dow? The averages committee explained

Više

Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection. It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007. Wikipedia

Glavni izvršni direktor

William H. Collier

Osnovano

2007

Sjedište

Warminster Township, Pennsylvania
Sjedinjene Američke Države

Web-lokacija

Zaposlenici

44

Pretraživanje

Izbriši pretraživanje

Zatvaranje pretraživanja

Googleove aplikacije

Glavni izbornik